 |
Live Webcast: Activate Today! Realize ROI with Intel® vPro Technology and Microsoft System Configuration Manager
Realize significant ROI savings-and recoup your investment in as little as 10 months-by activating your PCs with these proven technology solutions....
Sponsored by: Intel
Date: May 2009 |
|
- Show only
- White Papers
- Webcasts
- Case Studies
- Show all content
- Showing items 1-40 of 666
- « Previous | Next 40 »
 |
Intas Pharmaceuticals Intas Pharmaceuticals established its London office in Harrow, north west London in the summer of 2003. Intas Pharmaceuticals is among the fastest growing pharmaceutical ... Company: Think London | Think London |
|
IVAX Pharmaceuticals UK Limited Leading American drugs company, IVAX Pharmaceuticals Inc, set up IVAX Pharmaceuticals UK in 1994 in the Royal Docks, east London. In 1994 IVAX Corporation saw the opportu... Company: Think London | Think London |
 |
Best Practices for mySAP Pharmaceuticals
Best Practices for mySAP Pharmaceuticals is an integrated demonstration, evaluation, training, and implementation instrument that provides prepackaged business expertise ...
Company: SAP
Date: December 2001 |
|
|
Portals in the Pharmaceuticals Industry
In the pharmaceuticals industry, the overall focus in technology to date has been in implementing transactional ERP. Many of the advantages promised by eCommerce have not...
Company: Capgemini
Date: June 2004 |
Capgemini |
|
Business Case: Economic Benefits of EPC in Pharmaceuticals
There is a rapidly growing interest in applying Electronic Product Code (EPC) in pharmaceuticals, not only among drug companies and distributors, but also in the US Food ...
Company: Capgemini
Date: November 2004 |
Capgemini |
| More Search Results Below | ||
|
Variability and Growth in Spending for Outpatient Specialty Pharmaceuticals
Specialty pharmaceuticals are a unique group of drug agents used to treat complex clinical conditions. Many specialty pharmaceuticals are biological in nature and adminis...
Company: Project HOPE
Date: August 2005 |
Project HOPE |
|
Pharmaceuticals Industry Action Agenda
This paper, prepared as background to the development of the Pharmaceuticals Industry Action Agenda, presents an analysis of the pharmaceuticals industry and its role in ...
Company: Commonwealth of Australia
Date: September 2001 |
Commonwealth of Australia |
|
Demonstrating the Value of Pharmaceuticals Across the Healthcare Continuum
This document debates and explores medical innovation and the role of pharmaceuticals in the delivery of high-quality healthcare. This article examines and discusses the ...
Company: Managed Care
Date: February 2004 |
Managed Care |
|
Outlook: Potential and Pitfalls in Pharmaceuticals
There are potentially massive profits to be made in the pharmaceuticals' industry, if it can overcome the massive challenges posed by regulation, financing, and globaliza...
Company: President and Fellows of Harvard College
Date: April 2003 |
President and Fellows of Harvard College |
|
The Coming Paradigm Shift in Pharmaceuticals
This article explores the coming paradigm shift and the opportunities it presents for the future of pharmaceuticals. This article discusses how Pharmacogenomics holds the...
Company: Massachusetts Institute of Technology
Date: September 2002 |
Massachusetts Institute of Technology |
|
The Potential of Plant-Made Pharmaceuticals
With the advent of genetic modification technology, it is now possible to transfer human proteins into crop plants and use the plants as biological factories. This advanc...
Company: University of Maryland
Date: March 2003 |
University of Maryland |
|
Millennium Initiates Phase I Clinical Trial of MLN3897 In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN3897, the first compound to enter clinical trials from its inf... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
FDA Grants Millennium's MLN341 and MLN518 Fast Track Status
This article encapsulates and gives details about Millennium Pharmaceuticals. Millennium Pharmaceuticals is a leading biopharmaceutical company, applies its comprehensive...
Company: Millennium Pharmaceuticals
Date: June 2002 |
Millennium Pharmaceuticals |
|
High-Cost Users of Pharmaceuticals: Who Are They?
For a long time that health care resources and costs are concentrated on a relatively small proportion of the population. These high-level consumers of health care have g...
Company: University of Manitoba
Date: March 2005 |
University of Manitoba |
|
Millennium and Paion to Collaborate on Stroke Program
In this article Millennium Pharmaceuticals, Inc. and PAION GmbH summarize about the agreement to collaborate in the development of MLN519 for patients with stroke and cer...
Company: Millennium Pharmaceuticals
Date: March 2002 |
Millennium Pharmaceuticals |
|
Pharmaceuticals and Industrial Products in Crops: Economic Prospects and Impacts on Agriculture
With modern bio-manufacturing, common crop species can be genetically engineered to synthesize and deliver a broad range of unique bio-molecules needed for medical or ind...
Company: Iowa State University
Date: November 2004 |
Iowa State University |
|
Millennium Initiates Combination Oncology Trials of MLN341 With Taxotere
In this article Millennium Pharmaceuticals, Inc. discusses about the initiation of multiple phase I clinical trials of MLN341 (formerly LDP-341, PS-341), in combination w...
Company: Millennium Pharmaceuticals
Date: January 2002 |
Millennium Pharmaceuticals |
|
Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries
Parallel imports (PI), also called gray-market imports, are goods produced genuinely under protection of a trademark, patent, or copyright, placed into circulation in one...
Company: University of Colorado
Date: April 2001 |
University of Colorado |
|
Access to Medicines and Pharmaceutical Patents All countries agreed, in principle that, in circumstances of national health emergencies, developed countries should be allowed to grant compulsory licenses to manufactur... Company: Allens Arthur Robinson | Allens Arthur Robinson |
|
Waiving Informed Consent: Military Use of Non-FDA-Approved Drugs in Combat The 1991 Gulf War raised a number of ethical and policy questions regarding the use of investigational drugs to defend against chemical and biological warfare (CW/BW) age... Company: RAND | RAND |
|
R&D Administration With mySAP Pharmaceuticals
New drug application (NDA) approval is pivotal for pharmaceutical companies. After one wins approval, it's just a matter of marketing and selling the product. But achievi...
Company: SAP
Date: August 2004 |
|
|
A Trace-and-Track Future Tracking, security and traceability are driving pharmaceutical packaging as they never have before. New packaging machinery and coding technologies promise to improve pat... Company: Pharma Manufacturing | Pharma Manufacturing |
|
Pharmaceuticals/Health Care: Safety and Security in the Spotlight
This article discusses about the safety and security in healthcare and pharmaceutical sector. The U.S. business community?and society in general?have become markedly more...
Company: Helmers Publishing
Date: June 2004 |
Helmers Publishing |
|
Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection
In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application (MAA) to the European Agency for the Evaluat...
Company: Millennium Pharmaceuticals
Date: February 2003 |
Millennium Pharmaceuticals |
|
Millennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis In this article Millennium Pharmaceuticals, Inc and the Brigham and Women's Hospital presented results from seven studies in rheumatoid arthritis (RA) that could pave the... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Major Opportunities For Pharmaceuticals Companies Through Seamless Connections
In the pharmaceuticals industry, the overall focus in technology to date has been in implementing transactional ERP. Many of the advantages promised by eCommerce have not...
Company: Cap Gemini Ernst & Young
Date: January 2003 |
Cap Gemini Ernst & Young |
|
Enterprise Management and Support in the Life Sciences Industry
The Life Sciences Industry Three worldwide trends are driving increased consumption of pharmaceuticals and medical products: the aging of the baby boom generation, the le...
Company: SAP
Date: January 2005 |
|
|
FDA Approves VELCADE (Bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma This article discusses the Millennium Pharmaceuticals, Inc. approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of multiple myel... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
VELCADE (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. informs about the approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of multip...
Company: Millennium Pharmaceuticals
Date: May 2003 |
Millennium Pharmaceuticals |
|
A Healthy Regimen for Pharmaceuticals
The paper outlines that to succeed, companies need new competencies and capabilities, and they have to excel at them. The industry needs an aggressive, yet workable, plan...
Company: A.T. Kearney
Date: April 2004 |
A.T. Kearney |
|
A New Solution From TI, 3M and VeriSign to Secure the Pharmaceutical Supply Chain - How Does It Fit in With Current Industry Initiatives?
Texas Instruments, 3M, and VeriSign have come together to offer a solution designed to prevent the sale of counterfeit drugs to patients. Their solution utilizes radio fr...
Company: ABI Research
Date: May 2005 |
ABI Research |
|
Millennium Plans to Submit a New Drug Application for Velcade (Bortezomib) for Injection In this article Millennium Pharmaceuticals, Inc. informs that the Company intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) to... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Patents, Innovation and Access to New Pharmaceuticals
This paper considers the role of intellectual property rights in the development of and access to new pharmaceuticals. A number of studies have found patents are signific...
Company: Duke University
Date: July 2002 |
Duke University |
|
Canada and Brazil Dealing With Tension Between Ensuring Access to Medicines and Complying With Pharmaceutical Patent Standards: Is the Story the Same?
Health is a primary good which is fundamental for any person's life. As a result, health care services generally and pharmaceutical services (which is the focus of this r...
Company: University of Toronto
Date: June 2004 |
University of Toronto |
|
Pharmaceutical Technology Assessment for Managed Care: Current Practice and Suggestions for Improvement
Increasingly powerful pharmaceuticals are of increasing clinical and economic importance to managed care organizations. Expenditures on pharmaceuticals have also been inc...
Company: RAND
Date: August 2001 |
RAND |
|
Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN2704 (formerly known as MLN591DM1) in patients with metastatic...
Company: Millennium Pharmaceuticals
Date: November 2002 |
Millennium Pharmaceuticals |
|
FDA Accepts for Review NDA Filing and Grants Priority Review for Velcade (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. reveals that the U.S. Food and Drug Administration (FDA) accepted for review and granted Priority Review designation of t...
Company: Millennium Pharmaceuticals
Date: March 2003 |
Millennium Pharmaceuticals |
|
Short-Term Pain
People are nowadays unlike in the past paying more, either directly or through taxes, to ensure that they remain in good health. In this context the article shows that ov...
Company: Deloitte Touche Tohmatsu
Date: February 2005 |
|
|
Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses about the initiation of a phase I/II multiple ascending-dose clinical trial of MLN2704 in patients with metasta...
Company: Millennium Pharmaceuticals
Date: October 2003 |
Millennium Pharmaceuticals |
|
FDA Accepts sNDA Filing With Priority Review for VELCADE (Bbortezomib) for Injection to Treat Second-Line Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. informs that the U.S. Food and Drug Administration (FDA) accepted for review the Company's supplemental New Drug Applicat... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
- Showing items 1-40 of 666
- « Previous | Next 40 »
Submit a Paper
- Get your content listed in our directory! Our members are already finding your competitors' papers here -- shouldn't they find yours, too? It's FREE so click here and submit your white paper, case study, data sheet, research report, or other document today!
